Renovacare, Inc. · OTC:RCAR
Renovacare — Noble Capital Markets 17th Annual Investor Conference 2021
27 slides from Renovacare's conference presentation, Jan 20, 2021
Slide 1: Next Generation Cell Isolation & Ultra-Gentle Cell Spray
1 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 CellMist™ & SkinGun™ Symbol: RCAR RenovaCare | Noble Capital Markets 17 th Annual Investor Conference January 19, 2021 Next Generation Cell Isolation & Ultra - Gentle Cell Spray
Slide 2: Forward-looking statements
2 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 This slide deck and the accompanying oral presentation contain forward - looking statements, including, but not limited to, statements related to RenovaCare Inc . ’s future financial and ope
Slide 3: Today's Presenters
3 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Alan L. Rubino Chairman & CEO Robin A. Robinson, PhD Chief Scientific Officer Today’s Presenters
Slide 4: About RenovaCare
4 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare, Inc. (RCAR) is a biotechnology company focused on developing first - of - kind autologous (self - donated) stem cell therapies for the regeneration of human organs. Our initial p
Slide 5: RenovaCare: Past, Present and Future
5 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Development at StemCell Systems: SkinGun™ Cell Spray Device CellMist™ Cell Isolation Process Historical: Discovery Current: Clinical Future: Commercial Technology Evolution Company Focus Ele
Slide 6: Focused Strategies to Meet Long-Term Objectives
6 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 DIVERSE PRODUCT PORTFOLIO Burns, chronic wounds, acute wounds and scars ; regeneration of skin and other organs and tissues DISCIPLINED CAPITAL ALLOCATION Balanced to support portfolio growt
Slide 7: Next-Generation Biomedical Technologies Devices & Products
7 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Next - Generation Biomedical Technologies Devices & Products
Slide 8: Grafting is Painful, Expensive and Leaves Scarring
8 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Grafting is Painful, Expensive and Leaves Scarring Skin Grafting is Current Standard - of - Care Painful & Lengthy Treatment Cycle › 200 - year old method with the last breakthrough 50 years
Slide 9: RenovaCare Cell Isolation & SkinGun Procedure
9 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Step 1: Examine Wound/Harvest Donor Skin Tissue Performed bedside by the surgical burn team (15 min.) Step 2: Cell Isolation by Enzymatic Digestion in Cell Isolation Device Performed by burn
Slide 10: RenovaCare SkinGun Technology: 70+ Patients Treated
10 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare SkinGun™ Technology *Treated under special innovative practice approach at: Berlin - Brandenburg Center for Regenerative Therapies, Charité Berlin; and under innovative practice
Slide 11: RenovaCare Breakthrough Technology
11 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare Breakthrough Technology CellMist™ uses donor tissue sample. RenovaCare CellMist ™ Split Thickness Skin Graft 10cm 2 donor sample Donor Skin Sample 10cm 2 Typical › Small donor sk
Slide 12: RenovaCare Product Portfolio: 3 Select Multi-Tissue Cell Therapy Platforms
12 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 IDE/PMA 510(k) 510(k) 510(k) CellMist System™ Electronic SkinGun™ Autologous Skin Stem Cell Therapy for Burns POTENTIAL APPROVALS FROM 2021 - 2025 Disposable SkinGun™ Cell Spray Deposition
Slide 13: The RenovaCare Electronic SkinGun
13 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 The RenovaCare Electronic SkinGun™ OUR PATENTED CELL SPRAY TECHNOLOGIES SPRAY - ON STEM CELLS FOR RAPID HEALING Ultra - Gentle Deposition Ultra - Precise Even Distribution Even Droplets No
Slide 14: Research. Development. Innovation.
14 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Research. Development. Innovation.
Slide 15: RenovaCare R&D and Innovation Team
15 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Bioengineering & Cell Biology Regenerative Medicine Medical Device Engineering and Prototyping Regulatory - Centric IP Driven Engineering QMS Support Documentation RenovaCare R&D and Innova
Slide 16: Partners Enabling Clinical Pathway
16 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 R&D / QMS Clinical Manufacturing Regulatory Partners Enabling Clinical Pathway DATA - DRIVEN PARTNERS WITH AN UNWAVERING FOCUS ON IMPACT
Slide 17: RenovaCare IP Summary
17 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 RenovaCare IP Summary
Slide 18: Expanding Our Intellectual Property
18 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Cell spray device developed Disposable SkinGun™ Encompass all types of cell tissues or organs Modular handheld spray device for cells Additional IP filings Electronic SkinGun™ IP tested and
Slide 19: Disciplined Pathway & World Class Management
19 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Disciplined Pathway & World Class Management
Slide 20: Commercial Market Potential
20 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 $1B ~$600 - 700M ~$200 - 300M ~$2B in - patient burns severe second degree operation theater POTENTIAL TWO BILLION DOLLAR MARKET OPPORTUNITY WITHIN THE U.S. RenovaCare Regenerative Cell The
Slide 21: 2020-2021 Milestones / Goals
21 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Regulatory Priorities Planned Clinical Trials Corporate Development Activities Four Burn Center Sites: Q1 2021 FDA IDE Submission: Jul 2020 FDA IDE Cond App: Aug 2020 FDA IDE Final App: Q1
Slide 22: Experienced Leadership Team
22 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 COMMERCIALIZATION OPERATIONS REGULATORY R&D MANUFACTURING CLINICAL FULLY - INTEGRATED CAPABILITIES Alan L. Rubino CEO / President / Chairman Robert Cook Chief Financial Officer Dr. Robin Ro
Slide 23: Building For Success Focused On Results
23 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Building For Success Focused On Results
Slide 24: Financial Highlights
24 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 ~$266 Million Market Cap $8.7 Million Cash - on - Hand $8.6 Million Stockholders Equity Closing price at 5 - Jan - 2021: $3.05 Financials as of September 30, 2020 RenovaCare, Inc. Symbol: R
Slide 25: Building Shareholder Value
25 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Building Shareholder Value RenovaCare: Focused, Growing, Disciplined & Proven ▪ cell isolation and spray technologies ▪ stem cell therapies for acute and chronic wounds, including burns ▪ h
Slide 26: Questions & Answers
26 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 Questions & Answers
Slide 27: Thank you
27 © 2021 RenovaCare Inc. All rights reserved. Noble Capital Markets Annual Investor Conference I January 2021 spray - on stem cells for rapid healing . SkinGun™ & CellMist™ Next Generation Cell Isolation & Ultra - Gentle Cell Spray Symbol: RCAR Thank you for your participation. January 19, 2021 con
RenovaCare — Noble Capital Markets 17th Annual Investor Conference 2021 on 6ix